Federal policy relating to providing federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; and Federal policy relating to amending Hatch-Waxman Act 180-day NCE-1 exclusivity eligibility to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $220,000.00
- Registrant
- APOTEX CORP.
- Client
- APOTEX CORP.
- Filing UUID
- ad96bdae-40a3-4a91-867a-b23e106509c6
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.